ConductScience.org, home
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.
API referenceFor AI assistants

Paper · 27870574

Cited by241

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 354 citations.

1 to 20 of 241

Download this page as JSON
PMIDTitleJournalYearIn PapersSource
42,713,707Differential FGFR1 copy number status displays unique tumour immune microenvironment in triple-negative breast cancer.J Pathol2026https://conductscience.org/library/papers/42713707PubMed
42,633,326Advances in FGF/FGFR Signaling: Implications for Disease and Therapy.MedComm (2020)2026https://conductscience.org/library/papers/42633326PubMed
42,589,248Targeting Kinase Signaling in Glioblastoma: Structural Optimization, Blood-Brain Barrier Dynamics and Combinatorial Translational Strategies.Int J Mol Sci2026https://conductscience.org/library/papers/42589248PubMed
42,489,8927-azaindole as privileged scaffold: Advances in drug design and structural modification.Med Chem Res2026https://conductscience.org/library/papers/42489892PubMed
42,146,765Research on Targeted Therapy for Malignant Tumors of the Biliary Tract.Onco Targets Ther2026https://conductscience.org/library/papers/42146765PubMed
42,058,998FGFR alterations and potential role of FGFR inhibitors in pediatric brain tumors.Neurooncol Adv2026https://conductscience.org/library/papers/42058998PubMed
41,998,829FGFR1 Promotes Malignant Progression in Lung Squamous Cell Carcinoma Through Activation of Wnt/β-Catenin Signaling.Cancer Med2026https://conductscience.org/library/papers/41998829PubMed
41,850,040
Phase III trial of infigratinib versus gemcitabine/cisplatin in adults with advanced cholangiocarcinoma with FGFR2 gene fusion or rearrangement: results and reflections on early termination of PROOF 301.
ESMO Open2026https://conductscience.org/library/papers/41850040PubMed
41,804,750Multi-omic profiling defines three distinct molecular subtypes of urothelial carcinoma with implications for precision therapy.Clin Transl Med2026https://conductscience.org/library/papers/41804750PubMed
41,704,746Macrophage-Mediated Cellular Communication Networks in Lung Squamous Cell Carcinoma and Adenocarcinoma Revealed by Single-Cell Sequencing.Mediators Inflamm2026https://conductscience.org/library/papers/41704746PubMed
41,487,403Molecular mechanisms of human papillomavirus-induced tongue carcinogenesis: A systematic review.J Oral Biol Craniofac Res2026https://conductscience.org/library/papers/41487403PubMed
41,476,672The Landscape of Potential Targeted Treatments and Chemotherapy Efficacy Biomarkers for TNBC.Breast Cancer (Dove Med Press)2025https://conductscience.org/library/papers/41476672PubMed
41,310,273Towards biomarker-driven therapies for urothelial carcinoma.Nat Rev Clin Oncol2026https://conductscience.org/library/papers/41310273PubMed
41,263,060Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma.Mol Cancer Ther2026https://conductscience.org/library/papers/41263060PubMed
41,143,603PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models.Clin Cancer Res2026https://conductscience.org/library/papers/41143603PubMed
40,909,459Case Report: Neuroendocrine carcinoma of the breast: a review of the literature and illustration of six cases.Front Med (Lausanne)2025https://conductscience.org/library/papers/40909459PubMed
40,693,603Targeted therapies and immunotherapies for unresectable cholangiocarcinoma.Chin Med J (Engl)2025https://conductscience.org/library/papers/40693603PubMed
40,627,530Phase Ib Trial of Fulvestrant, Palbociclib, and Erdafitinib, a pan-FGFR Tyrosine Kinase Inhibitor, in HR+/HER2- Metastatic Breast Cancer.Clin Cancer Res2025https://conductscience.org/library/papers/40627530PubMed
40,526,877Functional Characterization of Variants of Unknown Significance of Fibroblast Growth Factor Receptors 1-4 and Comparison With AI Model-Based Prediction.JCO Precis Oncol2025https://conductscience.org/library/papers/40526877PubMed
40,518,115FGFs/FGFRs and neuroinflammatory diseases: mechanism, drug therapies and delivery systems.J Adv Res2025https://conductscience.org/library/papers/40518115PubMed

papers-2026-11-12-0.1.0

Next page

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/papers/v1/27870574/cited_by

API referenceFor AI assistants